Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company
Ocular Therapeutix (NASDAQ: OCUL) has unveiled new corporate branding to reflect its transformation into a retina-focused company. The rebranding features a new logo with a circular "O" representing the eye and retina, along with a full-spectrum color palette symbolizing human vision.
The company's primary focus is on disrupting retinal disease treatment, particularly wet age-related macular degeneration (AMD), which affects 1.8 million people in the U.S. Their investigational therapy, AXPAXLI™ (OTX-TKI), aims to address the limitations of current treatments that require up to 12 injections yearly and often lead to complications like fibrosis and atrophy.
Ocular Therapeutix (NASDAQ: OCUL) ha presentato un nuovo marchio aziendale per riflettere la sua trasformazione in un'azienda focalizzata sulla retina. Il rebranding include un nuovo logo con una "O" circolare che rappresenta l'occhio e la retina, accompagnato da una palette di colori a spettro completo che simboleggia la visione umana.
Il principale obiettivo dell'azienda è rivoluzionare il trattamento delle malattie retiniche, in particolare la degenerazione maculare umida legata all'età (AMD), che colpisce 1,8 milioni di persone negli Stati Uniti. La loro terapia sperimentale, AXPAXLI™ (OTX-TKI), mira a superare i limiti delle terapie attuali, che richiedono fino a 12 iniezioni all'anno e spesso causano complicazioni come fibrosi e atrofia.
Ocular Therapeutix (NASDAQ: OCUL) ha presentado una nueva identidad corporativa para reflejar su transformación en una empresa centrada en la retina. El cambio de imagen incluye un nuevo logo con una "O" circular que representa el ojo y la retina, junto con una paleta de colores de espectro completo que simboliza la visión humana.
El enfoque principal de la empresa es revolucionar el tratamiento de las enfermedades de la retina, especialmente la degeneración macular húmeda relacionada con la edad (AMD), que afecta a 1,8 millones de personas en EE.UU.. Su terapia en investigación, AXPAXLI™ (OTX-TKI), busca superar las limitaciones de los tratamientos actuales, que requieren hasta 12 inyecciones al año y con frecuencia causan complicaciones como fibrosis y atrofia.
Ocular Therapeutix (NASDAQ: OCUL)는 망막 중심 회사로의 변화를 반영하기 위해 새로운 기업 브랜드를 공개했습니다. 리브랜딩에는 눈과 망막을 상징하는 원형 "O" 로고와 인간의 시력을 상징하는 전체 스펙트럼 색상 팔레트가 포함되어 있습니다.
이 회사의 주요 목표는 특히 습성 연령 관련 황반변성(AMD) 치료를 혁신하는 것으로, 미국에서 180만 명이 영향을 받고 있습니다. 그들의 임상 시험 중인 치료제 AXPAXLI™ (OTX-TKI)는 연간 최대 12회의 주사가 필요하고 섬유증 및 위축과 같은 합병증을 자주 초래하는 기존 치료법의 한계를 극복하는 것을 목표로 합니다.
Ocular Therapeutix (NASDAQ : OCUL) a dévoilé une nouvelle identité visuelle pour refléter sa transformation en entreprise spécialisée dans la rétine. Le rebranding comprend un nouveau logo avec un "O" circulaire représentant l'œil et la rétine, ainsi qu'une palette de couleurs spectrales symbolisant la vision humaine.
La société se concentre principalement sur la révolution du traitement des maladies rétiniennes, en particulier la dégénérescence maculaire humide liée à l'âge (DMLA), qui touche 1,8 million de personnes aux États-Unis. Leur thérapie expérimentale, AXPAXLI™ (OTX-TKI), vise à surmonter les limites des traitements actuels, qui nécessitent jusqu'à 12 injections par an et entraînent souvent des complications telles que la fibrose et l'atrophie.
Ocular Therapeutix (NASDAQ: OCUL) hat ein neues Unternehmensbranding vorgestellt, das die Transformation zu einem auf die Netzhaut fokussierten Unternehmen widerspiegelt. Das Rebranding umfasst ein neues Logo mit einem kreisförmigen "O", das das Auge und die Netzhaut symbolisiert, sowie eine Farbpallette im Vollspektrum, die das menschliche Sehvermögen darstellt.
Der Hauptfokus des Unternehmens liegt darauf, die Behandlung von Netzhauterkrankungen zu revolutionieren, insbesondere die
- None.
- None.
The new branding showcases the Company's innovative vision for the future and mission to redefine the retina experience
BEDFORD, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, announced the launch of its new corporate branding and website today, marking the next milestone of the Company's transformation to a retina-focused company.
Ocular Therapeutix Logo
Designed with visual accessibility at its core, the logo is science-based, transformative, and joyful. The circular “O” represents the eye and the retina, while the full-spectrum color palette captures the vibrancy of human vision and the richness of life it enables. The treatment of the “X” represents the intersection of where the company has been and where it is going.
“Retinal disease, including wet age-related macular degeneration (AMD), remains a leading cause of blindness due to the high burden and pulsatile nature of available treatments,” said Pravin U. Dugel, MD, Executive Chairman, President, and CEO of Ocular Therapeutix. “At Ocular, we aim to redefine the retina experience to reduce that burden in hopes of preserving vision for the long-term. Our new branding reflects the meaningful progress we’ve made, driven by the momentum of our SOL trials and our commitment to patients.”
Ocular Therapeutix Anthem Video
Ocular Therapeutix: Retina Experience Redefined
A Media Snippet accompanying this announcement is available in this link.
Ocular’s top priority is to disrupt retinal disease treatment paradigms, starting with wet AMD which affects 1.8 million people in the U.S. alone. Current treatment options may require up to 12 injections per year, creating a heavy burden on patients and care partners that can lead to treatment discontinuation and poor long-term outcomes. With today’s pulsatile treatments, one in four patients develop fibrosis within two years and atrophy within five years.
Ocular Therapeutix’ investigational therapy, AXPAXLI™ (also known as OTX-TKI), is an axitinib hydrogel administered by intravitreal injection that has the potential to dramatically improve durability and long-term outcomes for patients with wet AMD and other retinal diseases.
The new corporate branding is now live across Ocular’s website, social media channels, and internal platforms, and will make its congress debut at the upcoming American Society of Retina Specialists (ASRS) conference, marking an exciting new chapter for the Company.
Explore the new corporate branding on our website.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company via its website, LinkedIn, or X.
DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c36052c2-ba6b-4175-806e-728f3e09ac1b
FAQ
What is the significance of Ocular Therapeutix (OCUL) new branding announcement?
What is AXPAXLI and how does it address wet AMD treatment challenges?
How many people are affected by wet AMD in the United States?
What are the current challenges in wet AMD treatment that Ocular Therapeutix aims to address?
